Ypsomed CEO: US production to begin in 2027

In an interview with Swissinfo, Simon Michel, CEO of Swiss medical device manufacturer, Ypsomed, explains why US tariffs represent only a limited challenge for his company and why he sees more growth from the success of GLP-1 drugs, blockbuster diabetes and obesity treatments such as Ozempic. Ypsomed is a global leader in drug delivery systems, technologies that allow patients to administer medicines themselves, such as self-injection pens for type 2 diabetes and obesity. The market for injection...